Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD

Mesoblast (ASX:MSB) has taken a step toward expanding the use of its flagship cell therapy Ryoncil, announcing a significant collaboration with the U.S. National Institutes of Health–funded Blood and Marrow Transplant Clinical Trials Network to conduct a pivotal trial in adults with severe steroid-refractory acute graft versus host disease. …